1. Home
  2. TRDA vs SMTI Comparison

TRDA vs SMTI Comparison

Compare TRDA & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$5.11

Market Cap

275.3M

Sector

Health Care

ML Signal

N/A

Logo Sanara MedTech Inc.

SMTI

Sanara MedTech Inc.

N/A

Current Price

$32.53

Market Cap

322.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRDA
SMTI
Founded
2016
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.3M
322.2M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
TRDA
SMTI
Price
$5.11
$32.53
Analyst Decision
Strong Buy
Hold
Analyst Count
7
3
Target Price
$18.75
★ $35.00
AVG Volume (30 Days)
★ 460.4K
95.7K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $25,421,000.00
$15,586,976.00
Revenue This Year
N/A
$13.07
Revenue Next Year
$709.43
$14.23
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 32.47
52 Week Low
$4.11
$16.05
52 Week High
$16.45
$35.52

Technical Indicators

Market Signals
Indicator
TRDA
SMTI
Relative Strength Index (RSI) 49.88 45.19
Support Level $4.18 $30.40
Resistance Level $5.13 $34.01
Average True Range (ATR) 0.49 1.00
MACD 0.12 0.06
Stochastic Oscillator 68.02 75.84

Price Performance

Historical Comparison
TRDA
SMTI

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About SMTI Sanara MedTech Inc.

Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.

Share on Social Networks: